This study evaluates the efficacy of photoacoustic/ultrasound (PA/US) imaging-based radiomics for distinguishing HER2-zero, HER2-low, and HER2-positive breast cancer (BC), aiming to enhance targeted therapy selection. Here, ERBB2 is linked to breast carcinoma.